2 weeks Ago
Motilal Oswal Securities has a buy call on Gland Pharma with a target price of Rs 1970. The current market price of Gland Pharma is Rs 1786.4.
Gland Pharma, incorporated in 1978, is a Small Cap company with a market cap of Rs 29372.76 crore, operating in the pharmaceuticals sector. Gland Pharma's key products/revenue segments include Pharmaceuticals, Sale of services, Export Incentives for the year ending 31-Mar-2024.
Financials For the quarter ended 30-09-2024, the company has reported a Consolidated Total Income of Rs 1465.49 crore, up .85% from last quarter Total Income of Rs 1453.
14 crore and up 2.73% from last year same quarter Total Income of Rs 1426.58 Crore.
Company has reported net profit after tax of Rs 163.53 Crore in latest quarter. Investment Rationale According to Motilal Oswal Financial Services, with two years of earnings decline for Gland Pharma in FY23/FY24, the earnings are largely at the trough and expected to experience revival over FY25-27.
They expect 20% earnings CAGR over FY25-27, led by increased volume offtake of base products such as enoxaparin, EBITDA break-even of Cenexi and subsequent better operating leverage, the additional business in the biologics segment, and commercialization of new products in the core market segment. Considering this outlook and stock trading at 16x/14x FY26/FY27 EV/EBITDA and 27x/22.5x FY26/FY27 PE, the brokerage reiterates a BUY.
Stock Trading Options Trading Made Easy: Options Trading Course By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Stock Trading Technical Trading Made Easy: Online Certification Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Algo Trading Made Easy By - Vivek Gadodia, Partner at Dravyaniti Consulting and RBT Algo Systems View Program Stock Trading Complete Guide to Stock Market Trading: From Basics to Advanced By - Harneet Singh Kharbanda, Full Time Trader View Program Stock Trading Options Scalping Made Easy By - Sivakumar Jayachandran, Ace Scalper View Program Stock Trading Introduction to Technical Analysis & Candlestick Theory By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Futures Trading Made Easy: Future & Options Trading Course By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Stock Trading RSI Made Easy: RSI Trading Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Renko Chart Patterns Made Easy By - Kaushik Akiwatkar, Derivative Trader and Investor View Program Stock Trading Stock Investing Made Easy: Beginner's Stock Market Investment Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Commodity Markets Made Easy: Commodity Trading Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Dow Theory Made Easy By - Vishal Mehta, Independent Systematic Trader View Program Stock Trading A2Z of Stock Market for Beginners: Stock Market Course For Beginners By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Market 104: Options Trading: Kickstart Your F&O Adventure By - Saketh R, Founder- QuickAlpha, Full Time Options Trader View Program Stock Trading Technical Analysis Made Easy: Online Certification Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Market 103: Mastering Trends with RMI and Techno-Funda Insights By - Rohit Srivastava, Founder- Indiacharts.com View Program Promoter/FII Holdings Promoters held 51.83 per cent stake in the company as of 30-Sep-2024, while FIIs owned 4.
47 per cent, DIIs 35.37 per cent. (You can now subscribe to our ETMarkets WhatsApp channel ).
